Skip to main content
CBTCabot CorporationSell5.7·$76.59

Cabot (CBT) Q2 2026 earnings — TrendMatrix coverage

BEAT+0.7% vs estimateEPS $1.67 vs $1.66 estVerdict Buy (Wait)Hold

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure

Event detail · Q2 2026

Key numbers

Adjusted EPS
$1.67
Estimate
$1.66
Surprise
+0.7%
Score at report (before → after)
5.95.9/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Report record · Q2 2026

How the report landed

Cabot (CBT) beat the $1.66 estimate with adjusted EPS of $1.67 — a modest 0.7% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.9/10) to Hold at 5.9/10 after the report.

Current read · as of 2026-09-22

Where TrendMatrix's rating stands now

TrendMatrix currently rates CBT Sell at 5.7/10.

4 of the last 4 quarters beat the estimate; this quarter's +0.7% surprise compares with a +5.7% four-quarter average. Next scheduled report: 2026-11-02.

What supports the rating

  • Strong earnings beat streak (4/4)
  • Attractive valuation

What argues against it

  • Thin upside margin: 3.7%
  • V7 low-quality RISK_OFF penalty: -0.5 (Q=5.3)
  • Sector modifier (Basic Materials): -0.1

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$76.59
Price target
$79.46
Stop
$73.75
Upside to target
+3.7%
Reward-to-risk
0.7:1

The stock trades at 21.7× trailing but 11.1× forward earnings — consensus estimates already build in a substantial earnings recovery.

Risk check: RSI 30 — a level conventionally read as oversold.

Model outputs from TrendMatrix’s engine as of 2026-09-22 — shown for context, not personalized investment advice.

Basic Materials context

CBT at TrendMatrix's latest read

Materials producers report against the commodity cycle — realized-price capture and volume, not the EPS line, are the tells in a quarter like this.

Industry
Specialty Chemicals
Market cap
$4.00B
P/E (fwd)
11.1
P/E (ttm)
21.7
52-week range
$58.33$94.53
Off 52-week high
19.0%
RSI (14)
30
Volume vs avg
0.83×
Score today
5.7/10

EPS and the estimate come from Yahoo Finance’s earnings calendar, captured around the report date. That EPS is the adjusted figure analysts forecast, so it can differ from the GAAP diluted EPS in the company’s filing, and consensus estimates vary between data providers. Revenue comes from SEC XBRL company facts where available, yfinance-provisional otherwise. Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home Stocks CBT Earnings Q2 2026 earnings